Suppliers

Baxter BioPharma Solutions

Baxter's BioPharma Solutions

Sterile Contract Manufacturing

With over 80 years of parenteral experience, BioPharma Solutions (a business unit of Baxter) offers a variety of contract manufacturing form/fill/finish services and solutions for injectables​ , designed to meet complex and traditional sterile manufacturing challenges.  In addition, we are the only CMO to offer a manufacturer-prepared, commercial-scale aseptic filling process for premixed drugs in flexible IV bags.

BioPharma Solutions provides our clients with confidence of delivery, service, and integrity​ - we know the work we do is ultimately vital to the patients you serve​.  Areas of expertise include:

  • Sterile Contract Manufacturing Solutions
    • Prefilled Syringe Filling
    • Liquid and Lyophilized Vial Filling
    • Cartridge Filling
    • Diluents for Reconstitution
    • Ampoule Filling
    • Powder Filled Vials
    • Sterile Crystallization
  • Parenteral Delivery Systems
    • Frozen Premix System
    • Liquid Premix System
    • BIO-SET Luer System
  • Drug Categories
    • Small molecules
    • Biologics
    • Vaccines
    • Cytotoxics
    • Antibody-Drug Conjugates (ADCs)
    • Highly potent compounds

 

BioPharma Solutions’ Halle and Bielefeld facilities in Germany are certified by SafeBridge doing both parenteral drug substance synthesis and parenteral drug product manufacturing and testing.  Baxter’s global presence​ provides opportunities for unique manufacturing collaborations and value for our partners.

Related resources

lyo_development

Best Practices in Formulation and Lyo Development

Baxter BioPharma Solutions | 13-Feb-2017 | Technical / White Paper

The ultimate goal of formulation development is a stable product. In the case of a protein product, that can be defined as delivering the correct dose,...

Pharmaceutical Development for ADCs

Pharmaceutical Development for ADCs

Baxter BioPharma Solutions | 08-Sep-2014 | Technical / White Paper

Formulation, process, and analytical development for antibody-drug conjugates, or ADCs, is complex.While the development of an aqueous solution formulation...